Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 93 peer-reviewed journal articles Updated
Oncology

Solitary Fibrous Tumor (SFT)

At a Glance

Solitary Fibrous Tumor (SFT) is a rare mesenchymal tumor driven by the NAB2-STAT6 gene fusion. Diagnosis is confirmed through STAT6 testing, and tumor behavior is predicted using the Demicco Risk Score. Treatment primarily involves surgery managed by sarcoma specialists, with long-term monitoring required.

Receiving a diagnosis of Solitary Fibrous Tumor (SFT) can be overwhelming. You are likely hearing terms you have never heard before, like “mesenchymal,” “NAB2-STAT6,” or “hemangiopericytoma.” You may have been told your tumor is “rare” or “unpredictable.”

This guide is designed to help you navigate this complex diagnosis. SFT is a unique type of tumor that doesn’t follow the standard rules of many other cancers. It requires a specific approach to diagnosis, treatment, and long-term monitoring.

How to Use This Guide

We have broken down the journey into five key sections. You can read them in order or jump to the topic that is most urgent for you right now.

01

What is Solitary Fibrous Tumor (SFT)?

Learn what Solitary Fibrous Tumor (SFT) is, how it relates to Hemangiopericytoma, and what the NAB2-STAT6 fusion means for your diagnosis and care.

02

Symptoms and Diagnosis of SFT

Learn about SFT symptoms, mass effect, and Doege-Potter Syndrome. Understand how CT scans, MRI flow voids, and STAT6 pathology confirm the diagnosis.

03

Understanding Your Risk: Grading and Staging

Learn how SFT risk is assessed using the Demicco Score and WHO Grading. Understand what mitotic count, necrosis, and tumor grade mean for your treatment.

04

Treatment Options for SFT

Explore Solitary Fibrous Tumor (SFT) treatments. Learn about surgical resection, radiation therapy, and targeted drugs like Pazopanib for advanced disease.

05

Living with SFT: Surveillance and Survivorship

Learn about life after SFT treatment. Understand the risk of late recurrence, your long-term surveillance schedule, and how to manage scanxiety effectively.

A Note on Expertise

Because SFT is rare, it is crucial to seek care from a center with experience in sarcomas or rare tumors. A “Sarcoma Specialist” will have the specific knowledge needed to manage the nuances of this disease.

Disclaimer: This guide is for informational purposes only and does not constitute medical advice. Always consult with your medical team for your specific care.

Common questions in this guide

What is Solitary Fibrous Tumor (SFT)?
Solitary Fibrous Tumor (SFT) is a rare type of tumor that develops in soft tissues. It is driven by a specific genetic fusion called NAB2-STAT6 and does not behave like common cancers, requiring a specialized approach to diagnosis and treatment.
Is SFT the same thing as Hemangiopericytoma?
Hemangiopericytoma is an older medical term that was previously used to describe these tumors. Doctors now understand that Hemangiopericytoma and SFT are biologically the same condition, so they are grouped together under the name Solitary Fibrous Tumor.
How do doctors diagnose SFT?
Doctors use a specific test called STAT6 immunohistochemistry to confirm SFT. This test looks for a specific protein in the tumor cells. If the result is positive for STAT6, it confirms the diagnosis of Solitary Fibrous Tumor.
Is Solitary Fibrous Tumor benign or malignant?
SFT is not strictly classified as just benign or malignant. Instead, doctors use risk stratification tools like the Demicco Risk Score and WHO Grading to predict how aggressive the tumor might be and the likelihood of it returning.
What kind of doctor should I see for SFT?
Because SFT is a rare condition, it is best treated by a sarcoma specialist. These doctors have specific experience with rare soft tissue tumors and understand the nuances of SFT management compared to general oncologists.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many cases of Solitary Fibrous Tumor (SFT) do you treat each year?
  2. 2.Is my case being reviewed by a multidisciplinary tumor board that includes sarcoma specialists?
  3. 3.Can you explain how the specific location of my tumor affects the treatment plan?
  4. 4.What is the specific plan for coordinating my care between surgery, oncology, and radiation therapy?
  5. 5.Are there any clinical trials for SFT that I should consider?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

This guide provides a general overview of Solitary Fibrous Tumor for educational purposes. It does not replace professional medical advice; always consult a sarcoma specialist for your specific care plan.

Get notified when new evidence is published on Solitary Fibrous Tumor (SFT).

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.